Browsing Tag
Denali Therapeutics is a biopharmaceutical company that is developing many different product candidates that are engineered to cross the blood-brain barrier for neurodegenerative diseases. Neurodegenerative diseases can be caused by damage or death of nerve cells in the brain. By developing drugs that can cross the blood-brain barrier, Denali Therapeutics hopes to provide treatments for these diseases.
The South San Francisco based company pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement.
